These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23242362)

  • 1. Dopamine dysregulation syndrome in Parkinson's disease patients with unsatisfactory switching from immediate to extended release pramipexole: a further clue to incentive sensitization mechanisms?
    Solla P; Cannas A; Corona M; Marrosu MG; Marrosu F
    Behav Neurol; 2013 Jan; 27(4):563-6. PubMed ID: 23242362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
    O'Sullivan SS; Evans AH; Lees AJ
    CNS Drugs; 2009; 23(2):157-70. PubMed ID: 19173374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole extended release in Parkinson's disease.
    Hametner EM; Seppi K; Poewe W
    Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
    Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
    Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term retention rate of pramipexole in the treatment of Parkinson's disease.
    Keränen T; Tuhkasaari M; Kuusisto H
    Eur J Clin Pharmacol; 2009 Sep; 65(9):955-6; author reply 957. PubMed ID: 19415250
    [No Abstract]   [Full Text] [Related]  

  • 7. Pramipexole extended release: in Parkinson's disease.
    Chwieduk CM; Curran MP
    CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
    Perez Lloret S; Rascol O
    Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
    Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
    Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial.
    Mizuno Y; Yamamoto M; Kuno S; Hasegawa K; Hattori N; Kagimura T; Sarashina A; Rascol O; Schapira AH; Barone P; Hauser RA; Poewe W;
    Clin Neuropharmacol; 2012; 35(4):174-81. PubMed ID: 22801294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
    Taguchi S; Niwa J; Ibi T; Doyu M
    Rinsho Shinkeigaku; 2015; 55(3):182-4. PubMed ID: 25786757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
    Frampton JE
    Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
    Ohno H; Nakajima M; Fujioka S; Iwamoto K; Kawamura M
    J Clin Neurosci; 2009 Jun; 16(6):790-2. PubMed ID: 19286385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonist induced compulsive eating behaviour in a Parkinson's disease patient.
    Khan W; Rana AQ
    Pharm World Sci; 2010 Apr; 32(2):114-6. PubMed ID: 20039208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panic attack like episodes possibly associated with pramipexole therapy in Parkinson's disease.
    Alonso-Navarro H; Jiménez-Jiménez FJ
    Eur J Neurol; 2007 May; 14(5):e1. PubMed ID: 17437590
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
    Shen T; Ye R; Zhang B
    Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease.
    Shen Z; Kong D
    Medicine (Baltimore); 2018 Aug; 97(34):e11316. PubMed ID: 30142750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compulsive drumming induced by dopamine agonists in Parkinson's disease: Another aspect of punding.
    Vitale C; Trojano L; Barone P; Errico D; Agosti V; Sorrentino G; Grossi D; Santangelo G
    Behav Neurol; 2013 Jan; 27(4):559-62. PubMed ID: 23242361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
    Bares M; Rektorová I; Krajcovicová L; Rektor I
    J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
    [No Abstract]   [Full Text] [Related]  

  • 20. Pramipexole-induced antecollis in Parkinson's disease.
    Suzuki M; Hirai T; Ito Y; Sakamoto T; Oka H; Kurita A; Inoue K
    J Neurol Sci; 2008 Jan; 264(1-2):195-7. PubMed ID: 17826796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.